2024 biotech funding tracker: recent highlights

Biotech investment january 2024

Discover the latest in biotech funding on our dedicated page. We meticulously curate and categorize significant fundraising events to keep you informed about the cutting-edge trends and investments driving the industry forward. Explore our tracker organized chronologically and by funding method, providing a comprehensive perspective on the ever-evolving world of biotech fundraising.

Would you like to receive our funding roundup directly in your inbox? Subscribe to our free newsletter for weekly updates straight to your inbox.

Recent biotech seed fundings

January 2024: 

  • Advesya (France): €23 million seed | cancer therapies
  • Cumulus Oncology (United Kingdom): £9 million ($11.45 million) seed | cancer drug discovery
  • DISCO Pharmaceuticals (Germany): EUR 20 million ($21.75 million) seed | drug discovery | map of small cell lung cancer surfaceome completed

February 2024: 

  • Alys Pharmaceuticals (United States): $100M seed | immuno-dermatology | clinical in skin diseases
  • Bioptimus (France): $35 million seed | AI-enabled drug discovery IsomAb (UK): £7.5 million ($9.46 million) seed | preclinical in peripheral arterial disease

March 2024:

  • Relation Therapeutics (United Kingdom): $35 million seed | multi omics for drug discovery | discovery in osteoporosis

April 2024:

  • Neurosterix (Switzerland): $63 million seed | allosteric modulator therapeutics | preclinical in schizophrenia
  • Seamless Therapeutics (Germany) : $12.5 million seed | gene editing
  • Outrun Therapeutics (United Kingdom) : $10 million seed | E3 ligase inhibitors | solid tumors
  • RevOpsis (United States) : $16.5 million seed | eye disease therapies | IND-enabling studies in age-related macular degeneration
  • Infinitopes (United Kingdom) : £12.8 million ($16.07 million) seed | cancer vaccines | preclinical in cancer

May 2024:

  • OverT Bio (United States) : $16 million seed | cell therapies | preclinical in solid tumors
  • Think Bioscience (United States): $6 million seed | small molecules | synthetic biology
  • Hephaistos Pharma (France): €10.3 million ($11.16 million) seed | cancer immunotherapies | preclinical in cancer
  • Limula (Switzerland): CHF 6.2 million ($6.78 million) seed | cell and gene therapies

Recent biotech series A funding rounds

January 2024: 

  • Claris Bio (United States): $57 million series A | corneal therapies | phase 1/2 clinical trial in neurotrophic keratitis
  • Resalis Therapeutics (Italy): €10 million ($10.95 million) series A | non-coded RNA-based therapeutics | phase 1 in obesity
  • OnCusp Therapeutics (United States): $100 million series A | oncology assets | preclinical in solid tumors
  • Myrobalan Therapeutics (United States): $24 million series A | CNS disease therapies | IND-enabling in multiple sclerosis, Alzheimer’s disease, and amyotrophic lateral sclerosis
  • Calluna Pharma (Norway): EUR 75 million ($81.71 million) series A | immune-related therapies | phase 1 in fibrosis
  • Tr1X, Inc. (United States): $75 million series A | regulatory T cell-based therapies | phase 1 in graft versus host disease
  • Granata Bio (United States): $14 million series A | women’s health | phase 3 in infertility
  • AQEMIA (France): €60 million ($65.02 million) series A | AI-enabled drug discovery
  • Imu Biosciences (United Kingdom): £11.5 million ($14.57 million) series A | immune discovery platform for precision medicines
  • Sagimet Biosciences (United States): $112.5 million series A | phase 3 in nonalcoholic steatohepatitis
  • COUR Pharmaceuticals (United States): $105 million series A | phase 2 in celiac disease
  • Synnovation Therapeutics (United States): $102 million series A | small molecule therapies | clinical in solid tumors
  • ZWI Therapeutics, Inc. (United States): $10 million series A | protein therapeutics | preclinical in refractory gout
  • Moonwalk Biosciences (United States): $57 million series A | precision epigenetic medicines

February 2024: 

  • Anbogen (Taiwan): $12.5 million series A | precision oncology | phase 2 in non-small cell lung cancer
  • Basking Biosciences (United States): $55 million series A | acute thrombolytic therapy | phase 2 in acute ischemic stroke
  • Latigo Biotherapeutics (USA): $135 million series A | non-opioid pain medicines | phase 1 in acute and chronic pain
  • Firefly Bio (USA): $94 million series A | degrader antibody conjugates | preclinical in solid and liquid tumors
  • Curve Therapeutics (UK): £40.5 million Series A | Small molecule drug discovery | Discovery stage in solid tumors
  • Baseimmune (UK): $11.3 million in Series A | AI-enabled vaccine platform | Preclinical in coronavirus

March 2024:

  • Kenai Therapeutics (USA): $82 million series A | stem cell therapy | preclinical in moderate to severe Parkinson’s disease.
  • Tierra Biosciences (United States): $11.4 million series A | AI-derived protein synthesis
  • Asgard Therapeutics (Sweden) | €30 million ($32.53 million) series A | cancer immunotherapies | preclinical in cancer
  • Mirador Therapeutics (United States) | $400 million series A | precision medicines
  • Clasp Therapeutics (United States) | $150 million series A | T cell engagers
  • Avenzo Therapeutics (United States) | $150 Million series A | cancer drugs | clinical in HR+ breast cancer
  • Edgewood Oncology (United States) | $20 million series A | cancer drugs | phase 1 in acute myeloid leukemia

April 2024:

  • Rhythm Pharmaceuticals (United States): $150 million series A | (MC4R) pathway-related treatments | phase 3 in obesity
  • Diagonal Therapeutics (United States) : $128 million series A | antibody discovery | preclinical in hereditary hemorrhagic telangiectasia
  • Seaport Therapeutics (United States) : $100 million series A | antidepressants and anxiolytics | phase 1 in major depression with anxiety
  • DeepCure (United States) : $24.6 million series A-1 | small molecules | discovery in inflammatory and immunological conditions
  • Corner Therapeutics (United States) : $54 million series A | cancer vaccines
  • Rubedo Life Sciences (United States) : $40 million series A | chronic disease therapies | IND-enabling in chronic atopic dermatitis and chronic psoriasis
  • Flindr Therapeutics (Netherlands) : €20 million ($21.38 million) series A | precision oncology | preclinical in ovarian cancer
  • Brise Pharmaceuticals (China) : $20 million in pre-series A and series A | pain management | phase 1 in chronic low back pain

May 2024: 

  • Reunion Neuroscience (United States) : $103 million series A | psychedelic treatments | phase 1 in postpartum depression
  • Enlaza Therapeutics (United States) : $100 million series A | covalent protein technology | preclinical in cancer
  • Delphia Therapeutics (United States) : $67 million series A | cancer therapies
  • Latus Bio (United States) : $54 million series A | gene therapies | preclinical in CNS diseases
  • Nabla Bio (United States): $26 million series A | protein design
  • Uniquity Bio (United States): $300 million financing | immunology | phase 2 in chronic obstructive pulmonary disease
  • Progentos Therapeutics (United States): $65 million series A | neuroscience | IND-enabling in depression
  • YGION Biomedical (Austria): €15 million ($16.26 million) series A | cancer immunotherapies

Recent biotech series B funding rounds

January 2024: 

  • Vico Therapeutics (Netherlands): $60 million (€54 million) series B | RNA modulation | phase 1/2 in spinocerebellar ataxia type 3
  • Full-Life Technologies (China, Belgium): $47.3 million series B | radionuclide drug conjugates | first-in-human trial in prostate cancer
  • Avistone Biotechnology (China): 1 billion Chinese yuan (~$140 million) series B | targeted cancer drugs | clinical in non-small cell lung cancer
  • HI-Bio (United States): $95 million series B | precision medicine | phase 2 in primary membranous nephropathy
  • Stalicla (Switzerland): $17.4 million series B | neurodevelopmental disorder-specific precision medicine platform | phase 1b in autism spectrum disorder
  • Cyrano Therapeutics (United States): $9 million series B | phase 2 in post-viral smell loss
  • Ratio Therapeutics (United States): $50 million series B | radiotherapies | phase 1 in epithelial-derived cancers
  • Comanche Biopharma (United States): $75 million series B | siRNA therapy | phase 1 in preeclampsia
  • Enterprise Therapeutics (United Kingdom): £26 million ($33.1 million) series B | respiratory diseases therapies | phase 2a in cystic fibrosis

February 2024: 

  • NeoPhore (United Kingdom): £9.6 million ($12.2 million) series B | immuno‑oncology therapies | drug discovery in solid tumors
  • Attralus (United States): $56 million series B | pan-amyloid removal therapeutics | phase 1 in systemic amyloidosis
  • ProfoundBio (United States): $112 million series B | antibody drug conjugates | phase 2 in solid tumors

March 2024:

  • BlossomHill Therapeutics (USA): $100 million series B | small molecule medicines | preclinical in oncology.
  • Nocion Therapeutics (USA): $62 million series B | small molecule medicines | phase 2b in chronic cough.
  • Engrail Therapeutics (United States) | $157 million series B | precision neuroscience | phase 2 in generalized anxiety disorder
  • Tubulis (Germany) | €128 million ($138.75 million) series B2 | antibody drug conjugates | preclinical in multiple solid tumors
  • Capstan Therapeutics (United States) | $175 million series B | RNA-based therapies | preclinical in autoimmune disorders

April 2024:

  • Alterome Therapeutics (United States) : $132 million series B | small molecules | IND-enabling studies in breast and endometrial cancers
  • TORL BioTherapeutics (United States) : $158 million series B-2 | antibody drug conjugates | early-stage clinical in CLDN 6+ tumors
  • SynOx Therapeutics (Ireland, United Kingdom) : $75 million series B | monoclonal antibodies | phase 3 in tenosynovial giant cell tumor
  • Pathios Therapeutics (United Kingdom) : $25 million series B | cancer therapies | preclinical in solid tumors
  • Cerevance (United States) : $47 million series B | neurodegenerative disease therapies | phase 3 in Parkinson’s disease

May 2024:

  • Qlaris Bio (United States) : $24 million series B | eye disease therapies | phase 1 in primary open angle glaucoma
  • Attovia Therapeutics (United States): $105 million series B | antibody-based therapies | preclinical in immune-mediated diseases
  • Brixton Biosciences (United States): $33 million series B | pain relief | preclinical in knee pain in osteoarthritis and after knee replacement surgery
  • AltruBio (United States): up to $225 million in series B round | immune checkpoint enhancers | phase 2a in ulcerative colitis
  • Pheon Therapeutics (United Kingdom): $120 million series B | antibody drug conjugates | preclinical in solid tumors
  • LabGenius (United Kingdom): £35 million ($44.54 million) series B | machine learning-driven drug discovery

Recent biotech series C funding rounds

January 2024:

  • Accent Therapeutics (United States): $75 million series C | small molecule therapies | IND-enabling in breast, ovarian, colorectal, and endometrial cancers
  • PRISM BioLab (Japan): 1.5 billion yen ($10.3 million) series C | drug discovery platform | phase 2 in cancer

February 2024: 

  • Halia Therapeutics (United States): $30 million series C | anti-inflammatory therapeutics | phase 2 in myelodysplastic syndromes
  • Frontier Medicines (USA): $80 million Series C | Precision medicine | Phase 1 in KRAS mutant cancers

March 2024:

  • Alumis (United States): $259 million series C | precision immunology | phase 2 in psoriasis
  • Sionna Therapeutics (United States): $182 million series C | small molecule therapies | phase 1 in cystic fibrosis
  • Siolta Therapeutics (United States): $12 million series C | live biotherapeutics | phase 2 in atopic dermatitis, food allergy and allergic asthma

April 2024:

  • Obsidian Therapeutics (United States) : $160.5 million series C | TIL therapy | phase 1 in melanoma
  • Asher Bio (United States) : $55 million series C | immunotherapies | phase 1 in solid tumors
  • Endeavor BioMedicines (United States) : $132.5 million series C | drug development | phase 2 in idiopathic pulmonary fibrosis

May 2024:

  • Zenas BioPharma (United States) : $200 million series C | autoimmune therapies | phase 3 in IgG4-related disease
  • Memo Therapeutics (Switzerland) : CHF 20 million ($22.01 million) series C extension | antibodies | phase 2/3 for BK virus infection in kidney transplant recipients
  • BioVersys (Switzerland) : CHF 12.3 million ($13.54 million) series C | antibacterial products | phase 2 in carbapenem resistant Acinetobacter baumannii infections
  • Bluejay Therapeutics (United States): $182 million series C | liver disease therapies | phase 2a in hepatitis D
  • Lycia Therapeutics (United States): $106.6 million series C | protein degradation | preclinical in autoimmune and inflammatory conditions
  • Ajax Therapeutics (United States): $95 million series C | JAK inhibitors | preclinical in myelofibrosis
  • Aardvark Therapeutics (United States): $85 million series C | small molecules | phase 2 in obesity

Recent biotech series D funding rounds

February 2024: 

  • BioAge (United States): $170 million series D | metabolic disease drug discovery platform | phase 2 in obesity

Recent biotech series E funding rounds

February 2024: 

  • Neurona Therapeutics (United States): $120 million series E | cell therapies | phase 1/2 in focal epilepsies

March 2024:

  • FogPharma (USA): $145 million series E | precision medicine | phase 1/2 in advanced or metastatic solid tumors.

Recent biotech PIPE fundings

January 2024: 

  • Immunic Therapeutics (United States): $240 million PIPE | small molecules | phase 3 in relapsing multiple sclerosis
  • ORIC Pharmaceuticals (United States): $125 million PIPE | cancer treatments | phase 1b in multiple myeloma
  • Kura Oncology (United States): $150 million PIPE | precision medicine | registration-directed trial in acute myeloid leukemia

February 2024: 

  • Adverum Biotechnologies (United States): $127.5 million PIPE | gene therapy | phase 2 in wet age-related macular degeneration
  • Silence Therapeutics (United Kingdom): $120 million PIPE | precision medicine | phase 2 in cardiovascular disease
  • BioSenic (Belgium): €500,000 ($538,000) PIPE | regenerative and immune medicine | phase 2b in chronic graft vs host disease
  • Mineralys Therapeutics (United States): $120 million PIPE | aldosterone synthase inhibitor | phase 2 in hypertension
  • Cogent Biosciences (USA): $225 million PIPE | precision medicine | phase 3 in gastrointestinal stromal tumors
  • Denali Therapeutics (USA): $500 million PIPE | Neurodegenerative disease therapeutics | Clinical in Hunter syndrome

March 2024:

  • Applied Therapeutics (USA): $100 million PIPE | aldose reductase inhibitors | phase 3 in galactosemia.
  • Regulus Therapeutics (United States): $100 million PIPE | RNA-based therapies | phase 1 in polycystic kidney disease
  • Lexeo Therapeutics (United States): $95 million PIPE | genetic medicines | phase 1/2 in cardiac Friedreich’s ataxia
  • Spyre Therapeutics (United States): $180 million PIPE | monoclonal antibodies | preclinical in inflammatory bowel disease
  • Cybin (Canada): $150 million PIPE | mental healthcare | phase 2 in major depressive disorder
  • Unicycive (United States): $50 million PIPE | kidney disease treatments | phase 1 in hyperphosphatemia
  • Elicio Therapeutics (United States): $6 million PIPE | immunotherapies | phase 2 in pancreatic ductal adenocarcinoma

April 2024:

  • Avalo (United States): $115.6 million PIPE | targeted therapies | phase 1 in hidradenitis suppurativa
  • CervoMed (United States): $50 million PIPE | neurodegenerative disease therapies | phase 2b ion dementia
  • Surrozen (United States): $17.5 million PIPE | targeted antibodies | phase 1 in severe alcoholic hepatitis
  • Acrivon Therapeutics (United States) : $130 million PIPE | precision proteomics | phase 2 in ovarian, endometrial, and bladder cancers
  • Protara Therapeutics (United States) : $45 million PIPE | cancer and rare disease therapies | phase 2 in non-muscle invasive bladder cancer
  • Cullinan Therapeutics (United States) : $280 million PIPE | modality-agnostic targeted therapies | phase 3 in non-small cell lung cancer
  • Eliem Therapeutics (United States, United Kingdom) : $120 million PIPE | nervous system disorder treatments | phase 1 in major depressive disorder
  • Century Therapeutics (United States) : $60 million PIPE | stem cell therapies | phase 1 in blood cancers
  • Leap Therapeutics (United States) : $40 million PIPE | cancer immunotherapies | phase 2 in gastric cancer
  • Zura Bio (United States) : $112.5 million PIPE | immunotherapies | phase 2 in autoimmune and inflammatory diseases
  • Korro Bio (United States) : $70 million PIPE | RNA editing | phase 1/2 in alpha-1 antitrypsin deficiency
  • Benitec Biopharma (United States) : $40 million PIPE | gene therapies | phase 1b/2a in oculopharyngeal muscular dystrophy
  • Cidara Therapeutics (United States) : $240 million PIPE | targeted immunotherapy | phase 2 in seasonal influenza

May 2024:

  • Context Therapeutics (United States) : $100 million PIPE | solid tumor therapies | preclinical in multiple solid tumors
  • Eledon Pharmaceuticals (United States) : $50 million PIPE | immune-modulating therapies | phase 2 in kidney transplantation
  • Plus Therapeutics (United States) : up to $18 million PIPE | radiotherapies | phase 2b in recurrent glioblastoma

Recent biotech IPOs and public offerings

January 2024:

  • Dyne Therapeutics (United States): $300 million public offering | oligonucleotide therapeutics | phase 1/2 in myotonic dystrophy type 1
  • Kymera Therapeutics (United States): $275 million public offering | targeted protein degradation | phase 2 in hidradenitis suppurativa and atopic dermatitis
  • Praxis Precision Medicines (United States): $150 million public offering | precision medicine | clinical in pediatric patients with early-onset SCN2A developmental and epileptic encephalopathy
  • Dyne Therapeutics (United States): $345.1 million public offering | muscle disease therapies | clinical in myotonic dystrophy type 1
  • XORTX (Canada): $2 million public offering | orphan disease indications | phase 2 in polycystic kidney disease
  • Immatics (Germany): $175 million public offering | phase 1 in recurrent and refractory solid tumors
  • Viridian Therapeutics (United States): $150 million public offering | antibody discovery and engineering | phase 3 in thyroid eye disease
  • TransCode Therapeutics (United States): $7.25 million public offering | clinical in metastatic cancer
  • Vaxcyte (United States): $750 million public offering | pneumococcal conjugate vaccines | phase 2 in pneumococcal disease
  • CG Oncology (United States): $380 million IPO | targeted oncolytic immunotherapy | phase 3 in bladder cancer
  • ArriVent Biopharma (United States): $175 million IPO | cancer therapeutics | phase 3 in non-small cell lung cancer
  • Tourmaline Bio (United States): $172.5 million public offering | immune and inflammatory disease therapies | phase 2 in thyroid eye disease
  • Panbela Therapeutics (United States): $9 million public offering | cancer therapies | phase 3 in pancreatic cancer

February 2024: 

  • Vaxcyte (United States): $862.5 million public offering | vaccine technology | phase 2 in pneumococcal disease
  • Vera Therapeutics (United States): $250 million public offering | immunologic disease therapeutics | phase 3 in IgA nephropathy
  • Alto Neuroscience (United States): $128.6 million IPO | precision medicine | phase 2b in major depressive disorder
  • Fractyl Health (United States): $110.0 million IPO | metabolic therapeutics | preclinical in obesity
  • Corbus Pharmaceuticals (United States): $94.5 million public offering | precision oncology | IND clearance in solid tumors |
  • Immix Biopharma (United States): $15 million public offering | cell therapy | phase 1b/2a in relapsed/refractory amyloidosis and relapsed/refractory multiple myeloma
  • Kyverna Therapeutics (United States): $319 million IPO | cell engineering | phase 2 in B-cell driven autoimmune diseases
  • Metagenomi (United States): $93.75 million IPO | precision genetic medicines | preclinical in hemophilia A
  • PepGen (United States): $80.1 million public offering | gene therapies | phase 2 in Duchenne muscular dystrophy
  • Tenax Therapeutics (United States): $9 million public offering | precision medicine | phase 3 in acute decompensated heart failure
  • Larimar Therapeutics (USA): $150 million public offering | rare disease therapeutics | phase 1 in Friedreich’s ataxia
  • Iovance Biotherapeutics (USA): $211 million underwritten offering | phase 3 in melanoma

March 2024: 

  • Viking Therapeutics (USA): $550 million public offering | metabolic and endocrine disorder therapies | phase 2b in nonalcoholic steatohepatitis.
  • BioVie (USA): $21 million public offering | liver and neurodegenerative disease therapeutics | phase 3 in Alzheimer’s disease.
  • Apogee Therapeutics (United States): $420 million public offering | biologics | phase 1 in atopic dermatitis
  • Eupraxia Pharmaceuticals (Canada): C$30 million ($22.23 million) public offering | precision medicine | phase 2 in osteoarthritis
  • Cognition Therapeutics (United States): $11.5 million public offering | CNS therapies | phase 2 in mild to moderate Alzheimer’s disease
  • Nkarta (United States): $240 million public offering | CAR NK cell therapies | phase 1 in lupus nephritis

April 2024: 

  • Praxis Precision Medicines (United States): $200 million public offering | central nervous system therapies | phase 3 in essential tremor
  • Boundless Bio (United States): $100 million initial public offering | precision oncology | phase 1 in oncogene-related cancers
  • Stoke Therapeutics (United States): $125 million public offering | RNA-based medicines | phase 1/2 in Dravet syndrome
  • Contineum Therapeutics (United States) : $110 million IPO | small molecules | phase 1 in idiopathic pulmonary fibrosis and multiple sclerosis
  • Longeveron (United States) : $5.25 million public offering | cell therapies | phase 2 in hypoplastic left heart syndrome
  • Nurix Therapeutics (United States) : $175 million public offering | small molecules and antibody therapies | phase 1 in B-cell cancers
  • TScan Therapeutics (United States) : $150 million public offering | T cell receptor therapies | phase 1 in blood cancers
  • Biohaven (United States) : $230 million public offering | neuroscience and cancer drugs | phase 3 in obsessive compulsive disorder
  • Longeveron (United States) : $11.4 million public offering | cell therapies | phase 2 in hypoplastic left heart syndrome
  • Mustang Bio (United States) : $4 million public offering | cell and gene therapies | phase 1 in non-Hodgkin lymphoma and chronic lymphocytic leukemia

May 2024:

  • Soleno Therapeutics (United States): $138 million public offering | rare disease therapies | phase 3 in Prader-Willi syndrome
  • Dyne Therapeutics (United States): $325.5 million public offering | muscle-targeted therapies | phase 1/2 in myotonic dystrophy type 1
  • Monte Rosa Therapeutics (United States): $100 million public offering | molecular glue degraders | phase 1/2 in MYC-driven cancers

Recent Post-IPO equity fundings

January 2024: 

  • Fortress Biotech (United States): $11 million Post-IPO equity | drug development | phase 3 in metastatic cancer
  • Vaxart (United States): $10 million Post-IPO equity | vaccine pills | phase 2 in Norovirus and COVID-19
  • Effector Therapeutics (United States): $15 million Post-IPO equity | selective translation regulator inhibitors | phase 2b in non-small cell lung cancer
  • Checkpoint Therapeutics (United States): $14 million Post-IPO equity | cancer therapies | awaiting approval for metastatic cutaneous squamous cell carcinoma drug
  • Voyager Therapeutics (United States): $100 million Post-IPO equity | neurogenetic medicine | IND-enabling studies in Alzheimer’s disease
  • Aptose (United States): $8.4 million Post-IPO equity | precision oncology | phase 1 in acute myeloid leukemia

February 2024: 

  • NexImmune (United States): $3.67 million Post-IPO equity | T cell-mediated therapies | phase 1/2 in acute myeloid leukemia
  • Jasper Therapeutics (United States): $50 million Post-IPO equity | antibody therapies | clinical in chronic spontaneous urticaria
  • CRISPR Therapeutics (Switzerland): $280 million Post-IPO equity | CRISPR/Cas9 technology | clinical in CD19+ malignancies and autoimmune diseases
  • Sensorion (France): €50.5 million ($54.04 million) Post-IPO equity | hearing loss restoration | phase in sudden sensorineural hearing loss
  • Clearside Biomedical (United States): $15 million Post-IPO equity | eyecare and drug delivery | phase 3 in uveitic macular edema

March 2024:

  • BioXcel Therapeutics (United States): $25 million Post-IPO equity | neuroscience and immuno-oncology | phase 3 in Alzheimer’s disease
  • Sangamo Therapeutics (United States): $24 million Post-IPO equity | genomic medicine | preclinical in chronic neuropathic pain

April 2024:

  • Vaccinex (United States): $1.5 million Post-IPO equity and PIPE | monoclonal antibodies | phase 2 in Alzheimer’s disease
  • Oculis (Switzerland) : $59 million Post-IPO equity | eye care | phase 3 in diabetic macular edema
  • Bio-Path Holdings (United States) : $1.2 million Post-IPO equity | RNA nanoparticle technology | phase 2 in blood cancers
  • Belite Bio (United States) : $25 million Post-IPO equity | RBP4 antagonists | phase 3 in dry age-related macular disease and Stargardt disease
  • INmune Bio (United States) : $9.7 million Post-IPO equity | immunology | phase 2 in Alzheimer’s disease

May 2024:

  • ADC Therapeutics (Switzerland) : $105 million financing | antibody-drug conjugates | phase 3 in large B cell lymphoma
  • Abeona Therapeutics (United States) : $75 million financing | gene therapies | phase 3 in recessive dystrophic epidermolysis bullosa
  • Aileron Therapeutics (United States) : $40 million financing | orphan pulmonary and fibrosis treatments | phase 1b in idiopathic pulmonary fibrosis
  • iTeos Therapeutics (United States, Belgium): $120 financing | cancer drugs | phase 2 in non-small cell lung cancer
  • Allogene Therapeutics (United States): $110 million financing | CAR T therapies | phase 2 in large b-cell lymphoma
  • Tevogen Bio (United States): up to $50 million in financing | T cell therapies | phase 1 in COVID-19
  • Erasca (United States): $160 million financing | cancer therapies | phase 3 in melanoma
  • Foghorn Therapeutics (United States): $110 million registered direct offering | precision medicine | phase 1 in acute myeloid leukemia
  • MaaT Pharma (France): €18 Million ($19.51 million) offering | microbiome therapies | phase 3 in acute graft versus host disease
  • Gt Biopharma (United States): $3.2 million registered direct offering | immunotherapy | phase 1 in acute myeloid leukemia and myelodysplastic syndromes

Recent Post-IPO debts

January 2024: 

  • BridgeBio Pharma (United States): up to $1.25 billion in Post-IPO Debt | genetic disease therapies | phase 3 in transthyretin amyloidosis

May 2024:

  • Adaptimmune (United States/United Kingdom): up to $125 million debt financing | T-cell therapies | FDA review for synovial sarcoma

Recent reserved offerings

April 2024:

  • Sensorion (France) : €15 million ($16.29 million) reserved offering | hearing disorder therapies | phase 2 in sudden sensorineural hearing loss

Other biotech fundings with unknown funding type

January 2024: 

  • Remix Therapeutics (United States): $60 million | RNA therapeutics | phase 1 in adenoid cystic carcinoma
  • C4 Therapeutics (United States): $25 million | targeted protein degradation | clinical in multiple myeloma & non-Hodgkin’s lymphoma
  • DelSiTech (Finland): €10 million ($10.88 million) | drug delivery | clinical in chronic hepatitis B
  • Locus Biosciences (United States): $23.9 million  | precision medicine | phase 2 in urinary tract infections
  • Eyconis (United States): launches with $150 million Series unknown | eyecare therapies

March 2024:

  • Mission Therapeutics (United Kingdom): £25.2 million ($​​32 million) | deubiquitylating enzyme inhibitors | phase 2 in cardiac surgery-associated kidney injury
  • Profluent (United States): $35 million financing | AI-enabled protein design

April 2024:

  • Sutro Biopharma (United States): $75 million | antibody drug conjugates | phase 2/3 in ovarian cancer
  • EnteroBiotix (United Kingdom) : £27 million ($34.27 million) financing | microbiome medicines | phase 2 in irritable bowel syndrome
  • Metsera (United States) : $290 million | obesity and metabolic disease medicines | phase 1 in obesity
  • Theolytics (United Kingdom) : £19 million ($24.5 million) financing | preclinical in ovarian cancer
  • Xaira Therapeutics (United States) : $1 billion financing | AI-based drug discovery and development
  • 4P-Pharma (France) : €15 million ($16.1 million) financing | drug development | phase 1 in osteoarthritis
  • Locate Bio (United Kingdom) : £9.2 million ($11.55 million) financing | orthobiologics | preclinical in chronic low back pain

May 2024:

  • BridgeBio (United States) : $200 million private financing | genetic disease and cancer therapies | phase 3 in transthyretin amyloidosis
  • X4 Pharmaceuticals (United States): $125 million financing | rare disease therapies | phase 2 in chronic neutropenic disorders
  • Cassava Sciences (United States): over $125 million | neuroscience | phase 3 in Alzheimer’s disease
  • Hercules CM NewCo (China): $400 million financing | obesity drugs | phase 2 in type 2 diabetes and obesity
inpart logo

Are you a looking for new funding opportunities and partners?

Join Inpart’s online partnering network to connect with decision-makers looking for the latest research, assets and expertise.

 

Additional resources and expert advice tips you might be interested in:

Newsletter Signup – Under Article / In Page

"*" indicates required fields

Subscribe to our newsletter to get the latest biotech news!

Name*
This field is for validation purposes and should be left unchanged.
Labiotech.eu